Medscape

Trial Shows Safety, Efficacy of 7-Day Buprenorphine Patch in Opioid-Naive Patients

September 28, 2010 (Las Vegas, Nevada) — A transdermal application system containing the partial μ-opioid receptor agonist buprenorphine showed analgesic efficacy in the treatment of low back pain in ...
Pharmabiz

Purdue Pharma gets US FDA nod for 15 mcg/hour dosage strength of Butrans transdermal system CIII

Purdue Pharma has received the US Food and Drug Administration (FDA) approval for a new 15 mcg/hour dosage strength of Butrans (buprenorphine) Transdermal System CIII, which will provide an additional ...
GEN

FDA Approves Purdue’s Opioid Patch for Chronic Pain

Transdermal system was shown to be effective in trials of patients with moderate to severe low-back pain. FDA approved Purdue Pharma’s Butrans™ Transdermal System CIII for the management of moderate ...
Business Wire

Elanco’s ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval

GREENFIELD, Ind.--(BUSINESS WIRE)--With the U.S. Food and Drug Administration (FDA) approval of Zorbium™ (buprenorphine transdermal solution), Elanco Animal Health (NYSE: ELAN) expands its pain ...
Healthline

Side Effects of Buprenorphine Patch and Sublingual Tablet

If you have certain conditions, you may be interested in learning more about buprenorphine. It’s a generic prescription drug that comes as an extended-release patch* and a sublingual tablet (a tablet ...
Medscape

FDA Approvals

FDA Approves Methylphenidate Patch for Teens With ADHD The FDA has approved an expanded age range for a methylphenidate transdermal system for the treatment of ADHD in adolescents aged 13 to 17 years.